Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
The chart shows the growth of an initial investment of $10,000 in Viking Therapeutics, Inc, comparing it to the performance of the S&P 500 index. All prices have been adjusted for splits and dividends.
Returns By Period
Viking Therapeutics, Inc (VKTX) has returned -2.08% so far this year and 67.39% over the past 12 months. Looking at the last ten years, VKTX has achieved an annualized return of 37.32%, outperforming the Benchmark (SPY), which averaged 12.23% per year.
VKTX
1M9.61%
6M13.91%
YTD-2.08%
1Y67.39%
5Y42.37%
10Y37.32%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Viking Therapeutics, Inc (VKTX) with color gradation from worst to best to easily spot seasonal factors.
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2026
-18.29%
18.12%
-1.39%
6.10%
2025
-19.61%
-8.00%
-15.41%
19.54%
-7.30%
-1.30%
23.61%
-15.47%
-2.67%
44.52%
-3.41%
-3.01%
2024
30.28%
217.08%
1.25%
-2.92%
-20.50%
-14.87%
6.78%
12.89%
-0.61%
14.74%
-28.14%
-23.21%
2023
-4.68%
24.97%
51.23%
26.66%
2.66%
-25.98%
-9.77%
-4.56%
-20.36%
-10.82%
25.46%
50.08%
2022
-20.56%
-9.70%
-10.45%
-20.93%
-6.72%
28.44%
4.51%
6.71%
-14.73%
48.55%
-2.64%
131.53%
2021
28.25%
-9.89%
-2.84%
0.63%
-19.01%
12.17%
1.65%
6.44%
-5.42%
-7.03%
-9.23%
-14.97%
2020
-23.88%
-6.92%
-21.61%
32.41%
27.68%
0.70%
-1.96%
-6.30%
-14.16%
-3.26%
14.21%
-12.44%
2019
10.27%
2.81%
17.49%
-22.86%
-2.53%
7.79%
-8.45%
-9.62%
-0.29%
-5.96%
12.79%
10.77%
2018
29.83%
18.34%
-29.74%
-4.85%
141.89%
-10.89%
7.26%
27.39%
31.67%
-25.27%
-16.99%
-33.59%
2017
17.50%
9.29%
-6.30%
-4.76%
-15.11%
-8.47%
-2.78%
0.97%
81.90%
18.41%
27.73%
33.11%
2016
2.11%
-5.48%
-10.64%
12.00%
-3.60%
-0.63%
-24.65%
0.93%
9.17%
Performance Indicators
The charts below present risk-adjusted performance metrics for Viking Therapeutics, Inc (VKTX) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of VKTX compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Viking Therapeutics, Inc volatility is 3.93%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses. Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Liabilities And Equity (USD)
715.73M
908.32M
368.49M
168.53M
210.66M
256.50M
284.26M
302.31M
22.12M
14.54M
15.44M
Equity Attributable To Parent (USD)
639.06M
880.28M
348.42M
145.32M
201.88M
244.34M
277.12M
297.75M
13.46M
8.04M
8.72M
Equity Attributable To Noncontrolling Interest (USD)
Viking Therapeutics, a clinical-stage biotech company, is developing VK2735, a dual GLP-1/GIP agonist for weight management currently in phase 3 trials. The company could potentially capture significant market share in the projected $100+ billion weight-loss market if VK2735 demonstrates efficacy comparable to Eli Lilly's Zepbound. However, the company faces substantial risks including clinical setbacks, intense competition, and the historical difficulty most biotechs face in achieving sustained success.
The Motley Fool•Prosper Junior Bakiny
AI Insight
While the company has promising clinical candidates and operates in a large growing market, the article emphasizes significant risks including above-average biotech failure rates, intense competition, and the need to demonstrate sustained innovation. The outcome is highly uncertain with potential for both substantial gains and bankruptcy.
Viking Therapeutics' VK2735, a GLP-1 weight loss drug candidate, could become a major player in the $100 billion weight loss market. Upcoming phase 3 clinical trial results could trigger a threefold stock surge if positive, making Viking an acquisition target. However, the investment is highly binary and risky, with significant downside if trials disappoint.
The Motley Fool•Thomas Niel
AI Insight
The article highlights significant upside potential with VK2735's promising phase 2 results and upcoming phase 3 trials that could lead to a 3x valuation increase and acquisition offers. However, this is tempered by acknowledgment of high binary risk.
Viking Therapeutics announced the completion of patient enrollment in its Phase 3 VANQUISH-2 clinical trial of VK2735, a dual GLP-1/GIP receptor agonist for obesity treatment. The trial enrolled approximately 1,000 adults with type 2 diabetes and obesity, randomized to receive VK2735 at various doses or placebo for 78 weeks. This marks the second of two registration studies to be fully enrolled, with results expected in 2027.
Benzinga•Prnewswire
AI Insight
Completion of enrollment in a major Phase 3 trial is a significant milestone demonstrating progress toward potential drug approval. The company's CEO highlighted the quick enrollment as evidence of market enthusiasm for obesity treatments. Positive Phase 2 data and advancement of multiple clinical programs support investor confidence.
The weight loss drug market presents significant growth opportunities. Eli Lilly leads the U.S. market with 60% share and generates triple-digit revenue growth from its tirzepatide products. Viking Therapeutics is advancing its VK2735 candidate through clinical trials with strong results. Lilly's stock has dropped 8% this year and trades at 28x forward earnings, potentially offering a buying opportunity, especially with upcoming regulatory decisions on its oral weight loss drug.
The Motley Fool•Adria Cimino
AI Insight
Strong clinical trial results for VK2735 candidate in both injectable and oral forms. Positioned to enter high-demand market with room for market share. Additional pipeline candidate targeting amylin and calcitonin receptors shows promise.
ACT Capital Management invested $7.25 million in Viking Therapeutics, acquiring 206,100 shares. Viking, a clinical-stage biotech company, is developing obesity and metabolic disorder treatments, with its lead candidate VK2735 showing promising Phase 2 results of up to 14.7% weight reduction. The company has $706 million in cash runway and is advancing multiple clinical programs including Phase 3 trials.
The Motley Fool•Jonathan Ponciano
AI Insight
Strong investor backing with $7.25M investment, promising Phase 2 data showing 14.7% weight reduction, substantial cash runway of $706M, and positioning in the high-growth obesity drug market with multiple clinical programs advancing to Phase 3.
Eli Lilly strengthened its leading position in the GLP-1 weight loss drug market with two major developments: Novo Nordisk's CagriSema failed to outperform Lilly's Zepbound in clinical trials, and Lilly launched a new convenient monthly-dose pen format for Zepbound. With 60% U.S. market share and a projected $100 billion market over four years, Lilly is well-positioned for continued growth, though competition from Pfizer and Viking Therapeutics remains a potential threat.
The Motley Fool•Adria Cimino
AI Insight
Identified as a potential market participant with weight loss drug candidates in clinical trials, but no specific product developments or competitive positioning details are provided.
Viking Therapeutics' weight-loss drug candidate VK2735 has posted strong mid-stage data and is in phase 3 clinical trials, positioning it as a potential disruptor in the rapidly growing obesity drug market. While the stock could deliver outstanding returns if it successfully navigates clinical and regulatory hurdles, investors should be aware of significant risks including potential clinical setbacks and increased market competition.
The Motley Fool•Prosper Junior Bakiny
AI Insight
Strong mid-stage trial data for VK2735, advanced stage of development (phase 3), multiple formulation approaches, and significant market opportunity in the rapidly growing weight-loss drug sector. However, sentiment is tempered by execution risks and regulatory uncertainties.
Viking Therapeutics (VKTX) shares surged 10.91% after Novo Nordisk's REDEFINE 4 trial failed to demonstrate non-inferiority for its obesity drug CagriSema compared to Eli Lilly's tirzepatide. The trial showed 20.2% weight loss with CagriSema versus 23.6% with tirzepatide. Viking's VK2735, a dual GLP-1/GIP agonist available in both injectable and oral forms, is positioned favorably as it enters Phase 3 trials in Q3 2026, with no competitors currently offering both formulations.
Benzinga•Vandana Singh
AI Insight
Stock gained 10.91% as competitor's trial failure strengthens Viking's market position. VK2735's dual injectable/oral formulation provides competitive advantage with no other dual/triple agonist currently available in both forms. Entering Phase 3 trials in Q3 2026 positions the company favorably in the growing obesity drug market.
Viking Therapeutics is positioned to capture significant market share in the rapidly expanding weight loss drug market, currently valued at $3.6B with potential to reach $35B if its VK2735 candidate succeeds in phase 3 trials. The obesity drug market is projected to reach nearly $100B by decade's end, with room for multiple competitors beyond current leaders Eli Lilly and Novo Nordisk.
The Motley Fool•Adria Cimino
AI Insight
Company has solid clinical trial results, is advancing VK2735 through phase 3 trials, and has significant room for market cap growth from current $3.6B valuation. Strong investor interest demonstrated by 121% stock surge on phase 2 data.
Viking Therapeutics is positioning itself as a serious contender in the rapidly growing weight loss drug market, expected to reach nearly $100 billion by decade's end. The company is advancing its dual GIP/GLP-1 receptor agonist candidate VK2735 through phase 3 trials in both injectable and oral formats, with key data releases and trial launches expected in 2026. While the company shows promise with an innovative pipeline, investors should weigh the clinical development risks against potential long-term growth opportunities.
The Motley Fool•Adria Cimino
AI Insight
Company is advancing promising weight loss drug candidates through late-stage trials with multiple catalysts expected in 2026, positioned in a high-growth market. However, sentiment is tempered by clinical development risks and lack of approved products on the market.
